clinical trial · NCT05779475
An Observational Study of Patients With Moderate Parkinson's Disease
Novo Nordisk A/S·—·enrolling by invitation·n = 96
Parkinson DiseaseNo treatment given
brief summary
The main purpose of this study is to follow and observe a group of people living with Parkinson's disease to see how study participation affects their signs and symptoms in the months after starting in the study. While taking part in this study participants will take their usual medication as prescribed. However, the study doctor may recommend adjustments to their medication to provide a better treatment of their Parkinson's disease. Participation will last from 3 up to 24 months. During visits to the clinic, the study doctor or study nurse will evaluate signs and symptoms of Parkinson's disease using several different assessments. At a minimum of 2 visits participants will be asked to undergo 'off'-assessments.
started
Apr 5, 2023
primary completion
Mar 11, 2030
completion
Mar 11, 2030
last updated
Dec 24, 2025
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol